KR20220154849A - 리소좀 축적 질환과 관련된 약제 조성물 및 용도 - Google Patents

리소좀 축적 질환과 관련된 약제 조성물 및 용도 Download PDF

Info

Publication number
KR20220154849A
KR20220154849A KR1020227039341A KR20227039341A KR20220154849A KR 20220154849 A KR20220154849 A KR 20220154849A KR 1020227039341 A KR1020227039341 A KR 1020227039341A KR 20227039341 A KR20227039341 A KR 20227039341A KR 20220154849 A KR20220154849 A KR 20220154849A
Authority
KR
South Korea
Prior art keywords
acetyl
leucine
lsd
disease
mps
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227039341A
Other languages
English (en)
Korean (ko)
Inventor
마이클 스트럽
Original Assignee
인트라바이오 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59859423&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20220154849(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1613828.1A external-priority patent/GB201613828D0/en
Priority claimed from GBGB1702552.9A external-priority patent/GB201702552D0/en
Priority claimed from GBGB1705762.1A external-priority patent/GB201705762D0/en
Priority claimed from GBGB1706854.5A external-priority patent/GB201706854D0/en
Application filed by 인트라바이오 리미티드 filed Critical 인트라바이오 리미티드
Priority to KR1020247021734A priority Critical patent/KR20240110078A/ko
Publication of KR20220154849A publication Critical patent/KR20220154849A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020227039341A 2016-08-11 2017-08-11 리소좀 축적 질환과 관련된 약제 조성물 및 용도 Ceased KR20220154849A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247021734A KR20240110078A (ko) 2016-08-11 2017-08-11 리소좀 축적 질환과 관련된 약제 조성물 및 용도

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
GB1613828.1 2016-08-11
GBGB1613828.1A GB201613828D0 (en) 2016-08-11 2016-08-11 Therapeutic agents for lysosomal storage disorders
GB1702552.9 2017-02-16
GBGB1702552.9A GB201702552D0 (en) 2017-02-16 2017-02-16 Therapeutic agents for lysosomal storage disorders
GB1705762.1 2017-04-10
GBGB1705762.1A GB201705762D0 (en) 2017-04-10 2017-04-10 Therapeutic agents for lysosomal storage disorders
GB1706854.5 2017-04-28
GBGB1706854.5A GB201706854D0 (en) 2017-04-28 2017-04-28 Therapeutic agents for lysosomal storage disorders
KR1020227009897A KR102467953B1 (ko) 2016-08-11 2017-08-11 리소좀 축적 질환과 관련된 약제 조성물 및 용도
PCT/IB2017/054928 WO2018029657A1 (en) 2016-08-11 2017-08-11 Pharmaceutical compositions and uses directed to lysosomal storage disorders

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020227009897A Division KR102467953B1 (ko) 2016-08-11 2017-08-11 리소좀 축적 질환과 관련된 약제 조성물 및 용도

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247021734A Division KR20240110078A (ko) 2016-08-11 2017-08-11 리소좀 축적 질환과 관련된 약제 조성물 및 용도

Publications (1)

Publication Number Publication Date
KR20220154849A true KR20220154849A (ko) 2022-11-22

Family

ID=59859423

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020227039341A Ceased KR20220154849A (ko) 2016-08-11 2017-08-11 리소좀 축적 질환과 관련된 약제 조성물 및 용도
KR1020227009897A Active KR102467953B1 (ko) 2016-08-11 2017-08-11 리소좀 축적 질환과 관련된 약제 조성물 및 용도
KR1020247021734A Pending KR20240110078A (ko) 2016-08-11 2017-08-11 리소좀 축적 질환과 관련된 약제 조성물 및 용도
KR1020197007024A Active KR102412724B1 (ko) 2016-08-11 2017-08-11 리소좀 축적 질환과 관련된 약제 조성물 및 용도

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020227009897A Active KR102467953B1 (ko) 2016-08-11 2017-08-11 리소좀 축적 질환과 관련된 약제 조성물 및 용도
KR1020247021734A Pending KR20240110078A (ko) 2016-08-11 2017-08-11 리소좀 축적 질환과 관련된 약제 조성물 및 용도
KR1020197007024A Active KR102412724B1 (ko) 2016-08-11 2017-08-11 리소좀 축적 질환과 관련된 약제 조성물 및 용도

Country Status (30)

Country Link
US (4) US11400067B2 (https=)
EP (4) EP3482754B1 (https=)
JP (4) JP7393943B2 (https=)
KR (4) KR20220154849A (https=)
CN (3) CN109843275B (https=)
AU (3) AU2017308864B2 (https=)
CA (1) CA3033557A1 (https=)
CY (2) CY1121345T1 (https=)
DK (2) DK3359146T3 (https=)
ES (2) ES2849566T3 (https=)
FI (1) FIC20260014I1 (https=)
HK (1) HK1253282B (https=)
HR (2) HRP20190344T1 (https=)
HU (2) HUE052837T2 (https=)
IL (2) IL314107A (https=)
LT (2) LT3482754T (https=)
MA (2) MA43876B1 (https=)
MD (2) MD3359146T2 (https=)
ME (1) ME03340B (https=)
MX (2) MX384447B (https=)
NZ (3) NZ790895A (https=)
PL (2) PL3482754T3 (https=)
PT (2) PT3482754T (https=)
RS (2) RS61442B1 (https=)
RU (1) RU2749515C2 (https=)
SG (1) SG11201901048VA (https=)
SI (2) SI3359146T1 (https=)
SM (2) SMT202100050T1 (https=)
TN (1) TN2019000032A1 (https=)
WO (1) WO2018029657A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3359146T3 (en) * 2016-08-11 2019-04-08 Intrabio Ltd PHARMACEUTICAL COMPOSITIONS AND USES AGAINST LYSOSOMAL STORAGE DISEASES
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
EP3886986A1 (en) * 2018-12-06 2021-10-06 IntraBio Ltd Deuterated analogs of acetyl-leucine
SMT202400334T1 (it) * 2019-03-02 2024-09-16 Intrabio Ltd (n-)acetil-l-leucina per il trattamento di lesioni cerebrali traumatiche
RS67283B1 (sr) 2019-06-28 2025-11-28 Intrabio Ltd Kombinovana terapija sa acetil-leucinom i miglustatom za lečenje bolesti lizozomskog skladištenja
WO2022264037A1 (en) * 2021-06-14 2022-12-22 Intrabio Ltd. Branched-chain amino acid derivatives to treat disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2749512B1 (fr) * 1996-06-10 1999-08-13 Pf Medicament Utilisation de l'acetyl dl leucine pour le traitement des tremblements
AU2001269923A1 (en) 2000-06-19 2002-01-02 Genzyme Corporation Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
FR2883180B1 (fr) 2005-03-18 2007-05-25 Pierre Fabre Medicament Sa Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre
FR2905600B1 (fr) 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
WO2009114729A2 (en) * 2008-03-14 2009-09-17 Irm Llc Compounds, compositions and methods for treating lysosomal storage diseases and disorders
TN2010000251A1 (fr) 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
TN2010000566A1 (en) 2010-12-03 2012-05-24 Rekik Raouf Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs
GB201114017D0 (en) 2011-08-15 2011-09-28 Univ Dundee Inhibitors against endosomal/ysosomal enzymes
JP2015518872A (ja) 2012-06-06 2015-07-06 フォンダッツィオーネ・テレソン アロステリックシャペロンおよびその使用
KR102247701B1 (ko) 2016-02-26 2021-05-03 한미정밀화학주식회사 폴리에틸렌글리콜 디알데히드 유도체의 제조방법
WO2018029658A1 (en) 2016-08-11 2018-02-15 Intrabio Limited Therapeutic agents for neurodegenerative diseases
DK3359146T3 (en) 2016-08-11 2019-04-08 Intrabio Ltd PHARMACEUTICAL COMPOSITIONS AND USES AGAINST LYSOSOMAL STORAGE DISEASES

Also Published As

Publication number Publication date
AU2023202903A1 (en) 2023-05-25
CY1121345T1 (el) 2020-05-29
SMT201900154T1 (it) 2019-05-10
ES2716133T3 (es) 2019-06-10
RU2021115932A (ru) 2021-06-08
US12433862B2 (en) 2025-10-07
LT3482754T (lt) 2021-05-10
NZ790894A (en) 2026-03-27
JP2025188157A (ja) 2025-12-25
CY1123844T1 (el) 2022-05-27
JP7393943B2 (ja) 2023-12-07
MD3482754T2 (ro) 2021-05-31
RS58478B1 (sr) 2019-04-30
IL314107A (en) 2024-09-01
EP3482754A1 (en) 2019-05-15
HRP20190344T1 (hr) 2019-04-19
CN109843275A (zh) 2019-06-04
US12433863B2 (en) 2025-10-07
RU2019106493A3 (https=) 2020-10-26
US20190201359A1 (en) 2019-07-04
CN121360108A (zh) 2026-01-20
FIC20260014I1 (fi) 2026-04-27
MX384447B (es) 2025-03-14
SI3359146T1 (sl) 2019-05-31
US20240197663A1 (en) 2024-06-20
NZ790895A (en) 2026-03-27
EP3482754B1 (en) 2020-12-23
US11400067B2 (en) 2022-08-02
PL3359146T3 (pl) 2019-07-31
IL264610B1 (en) 2024-08-01
MX2019001577A (es) 2019-08-29
SMT202100050T1 (it) 2021-03-15
HUE041914T2 (hu) 2019-06-28
KR20220044372A (ko) 2022-04-07
EP3359146A1 (en) 2018-08-15
ES2849566T3 (es) 2021-08-19
IL264610A (en) 2019-02-28
EP3865126A1 (en) 2021-08-18
KR20190039226A (ko) 2019-04-10
US20260027077A1 (en) 2026-01-29
HK1253282A1 (en) 2019-06-14
AU2017308864B2 (en) 2023-06-01
CA3033557A1 (en) 2018-02-15
KR20240110078A (ko) 2024-07-12
HRP20210153T1 (hr) 2021-05-28
MA43876A (fr) 2018-08-15
ME03340B (me) 2019-10-20
KR102412724B1 (ko) 2022-06-23
AU2025203479A1 (en) 2025-05-29
AU2017308864A1 (en) 2019-02-21
PL3482754T3 (pl) 2021-07-05
IL264610B2 (en) 2024-12-01
BR112019002719A2 (pt) 2019-05-14
SG11201901048VA (en) 2019-03-28
JP7757446B2 (ja) 2025-10-21
MX2021008432A (es) 2021-08-19
MD3359146T2 (ro) 2019-04-30
JP2019524821A (ja) 2019-09-05
PT3359146T (pt) 2019-03-27
MA55947A (fr) 2022-03-23
PT3482754T (pt) 2021-02-03
RU2749515C2 (ru) 2021-06-11
WO2018029657A1 (en) 2018-02-15
LT3359146T (lt) 2019-04-25
TN2019000032A1 (en) 2020-07-15
AU2023202903B2 (en) 2025-03-06
JP2022050564A (ja) 2022-03-30
DK3359146T3 (en) 2019-04-08
RS61442B1 (sr) 2021-03-31
EP4342461A2 (en) 2024-03-27
HK1253282B (en) 2020-02-07
SI3482754T1 (sl) 2021-04-30
DK3482754T3 (da) 2021-02-01
CN121360107A (zh) 2026-01-20
KR102467953B1 (ko) 2022-11-16
CN109843275B (zh) 2026-04-24
NZ750391A (en) 2026-03-27
EP4342461A3 (en) 2024-05-29
RU2019106493A (ru) 2020-09-11
MA43876B1 (fr) 2019-04-30
HUE052837T2 (hu) 2021-05-28
JP2024059863A (ja) 2024-05-01
US20220331278A1 (en) 2022-10-20
EP3359146B1 (en) 2019-01-23

Similar Documents

Publication Publication Date Title
KR102413756B1 (ko) 신경퇴행성 질병을 위한 치료제
KR102467953B1 (ko) 리소좀 축적 질환과 관련된 약제 조성물 및 용도
US12458614B2 (en) Therapeutic agents for improved mobility and cognitive function and for treating neurodegenerative diseases and lysosomal storage disorders
RU2853626C2 (ru) Фармацевтические композиции и применения против лизосомных болезней накопления
HK40101408A (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders
HK40050066A (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders
BR112019002719B1 (pt) Uso de uma acetil-leucina ou um sal farmaceuticamente aceitável da mesma

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0601 Decision of rejection after re-examination

St.27 status event code: N-2-6-B10-B17-rex-PX0601

X601 Decision of rejection after re-examination
T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104